PubMed دسترسی آزاد

Artificial intelligence and computational methods in the Asia-Pacific pharmacovigilance landscape: a systematic review.

استودیوی صوتی مقاله

پخش حرفه‌ای فارسی و انگلیسی

در حال بررسی نسخه‌های صوتی ذخیره‌شده…

صوت تولیدشده با هوش مصنوعی است. برای کاربرد علمی یا درمانی، متن و منبع اصلی را بررسی کنید.
خواندن هوشمند فارسی و انگلیسی در حال آماده‌سازی صداهای مرورگر…
تنظیم صدای طبیعی و سرعت

صداهایی که در نامشان «Natural»، «Neural» یا «Online» دیده می‌شود معمولاً طبیعی‌ترند. انتخاب صدا به صداهای نصب‌شده در ویندوز و مرورگر شما بستگی دارد.

چکیده اصلی

OBJECTIVE: To examine the application of artificial intelligence (AI) in pharmacovigilance across the Asia-Pacific and identify reported methodological implementation challenges. METHODS: MEDLINE, Scopus, and Google Scholar were searched using terms related to artificial intelligence, computational signal detection, pharmacovigilance, and Asia-Pacific countries. Peer-reviewed original studies published in English were included. PRISMA 2020 guideline was followed. RESULTS: We included 64 studies in 14 countries primarily focused on 1) Adverse Drug Reaction (ADR) identification, 2) ADR prediction and risk factor modelling, 3) Drug safety, monitoring, and evaluation, 4) Predictive modelling, and 5) Data information management. Machine Learning (ML) techniques were the most commonly applied AI methods in pharmacovigilance, followed by natural language processing, deep learning, neural networks, and symbolic and explainable AI. Disproportionality analysis methods were also commonly used across studies. Some challenges reported were relevant to data quality issues, generalizability, clinical workflow integration, implementation technicalities, and cultural barriers. CONCLUSION: To overcome the challenges of AI application in the Asia-Pacific, a tiered implementation strategy can be employed through establishing a regional collaboration framework and taking into account disparities in technological maturity across countries.

متن کامل اصلی

نسخه دارای مجوز در منبع علمی در دسترس است.

لینک مستقیم از metadata منبع گرفته شده و در تب جدید باز می‌شود.

باز کردن متن کامل

کلیدواژه‌ها

AIAsia-pacificartificial intelligencedrug safetypharmacovigilance
در همین زیرشاخه

مقاله‌های مرتبط

PubMed2026

GLP-1R expression and dermatological diseases: a mendelian randomization and real-world study.

BACKGROUND: Although glucagon-like peptide-1 receptor (GLP-1R) is widely expressed in multiple tissues and organs including skin and subcutaneous tissue, with diverse physiological roles in metabolism and immunity, the potential causal association between GLP-1R expression and dermatological diseases remains unclear. METHODS: Available cis-expression quantitative trait loci (cis-eQTLs) were selected as genetic instruments for GLP-1R ex…

PubMed2026

Machine learning-driven pharmacovigilance of antidiabetic drugs: comparative reporting patterns and classification of serious adverse events.

PURPOSE: This study aims to evaluate the comparative adverse drug event (ADE) reporting patterns associated with antidiabetic drugs and develop machine learning (ML)-based classification models for the seriousness of reported ADEs. METHODS: We performed a retrospective analysis of 28,633 antidiabetic-related ADEs reported to the Korea Institute of Drug Safety and Management- Korea Adverse Event Reporting System database (KAERS DB 2505A…

PubMed2026

Artificial Intelligence Across the Pharmaceutical Life Cycle: Implications for Industry-Based Clinical Pharmacists.

Artificial intelligence (AI) is increasingly shaping the pharmaceutical industry. This ACCP commentary examines the implications of AI for industry-based clinical pharmacists across the pharmaceutical life cycle, including drug development, regulatory affairs, medical affairs, health economics and outcomes research, and pharmacovigilance. Artificial intelligence-enabled tools may support target identification, clinical trial design, re…

PubMed2026

FAERS-based pharmacovigilance study of sevoflurane-associated adverse events: A 20-year comprehensive analysis.

BACKGROUND: Sevoflurane, an ether-derived inhalational anesthetic widely used for general anesthesia, requires comprehensive safety evaluation. OBJECTIVES: This study aimed to identify sevoflurane-associated adverse events and detect unexpected safety signals using data from the FDA Adverse Event Reporting System (FAERS). METHODS: We analyzed FAERS data from the first quarter of 2004 through the first quarter of 2024, applying four dis…